Takeda Halts Domestic Phase III AMG479 Trial For Pancreatic Cancer
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceuticals announced Aug. 9 it decided to halt Phase III trials of the antibody drug AMG479 (ganitumab) for pancreatic cancer.